Table 3

Comparison of three different strategies to use (combined) biomarkers for the decision to stop or continue treatment

StrategyS100A12hsCRPMRPnDecision would beFlare within 0-6 months (%)No flare within 0-6 months (%)Decision could be wrong, n (%)
Early withdrawal preferred: single marker S100A12Low150Stop treatment19 (13)131 (87)19 (13)
High36*Continue treatment15 (42)21 (58)21 (58)
Longer treatment: combined ‘S100A12 or hsCRP’LowANDLow132Stop treatment12 (9)120 (91)12 (9)
HighORHigh54Continue treatment22 (41)32 (59)32 (59)
Highest safety: all markers combinedLowANDLowANDLow99Stop treatment8 (8)91 (92)8 (8)
HighORHighORHigh87Continue treatment26 (30)61 (70)61 (70)
  • * Two patients with missing hsCRP results have been excluded.

  • hsCRP, high-sensitivity C reactive protein.